Recent Updates
Recently added Catalysts

CK-2017357

Phase 3

Amyotrophic Lateral Sclerosis | Small molecule | Neurology |Cytokinetics, Incorporated|Trials Updated: Jun 15, 2021

CK-2017357 development status

Highest phase Phase 3 (NCT02936635)
Phase scored for CYTKPhase 2
Registered trials 4 across 1 sponsor since Dec 2011

CK-2017357 target and mechanism

ModalitySmall molecule

Also known as CK-2017357 (Part A), tirasemtiv

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials7
Total Enrollment1,939

FDA Designations

No designations recorded

CK-2017357 clinical trials

CK-2017357 · 7 trials · 4 indications

Phase 3 2Phase 2 5
NCT02936635A Study for Patients Who Completed VITALITY-ALS (CY 4031)Amyotrophic Lateral Sclerosis (ALS)
COMPLETED280 Analytics
NCT02496767Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a YearAmyotrophic Lateral Sclerosis
COMPLETED744 Analytics
PHASE3COMPLETED
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
Amyotrophic Lateral Sclerosis (ALS)Unlock trial analytics
PHASE3COMPLETED
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year
Amyotrophic Lateral SclerosisUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants With Adverse Events
From the first dose of tirasemtiv through 28 days after the last dose

The number of participants with adverse events was used as the measure for the long-term safety and tolerability of tirasemtiv.

Change From Baseline to Week 24 of the Double-blind, Placebo-controlled Phase in Percent Predicted Slow Vital Capacity (SVC)
24 weeks

SVC was measured using a spirometer (in units of liters). Following 3 to 5 breaths at rest, the patients were instructed to take as deep an inspiration as possible followed by a maximum exhalation (blowing out all the air in their lungs). Values obtained were converted to % predicted values (ie, the test result as a percent of predicted values for patients of similar demographic and baseline characteristics \[eg, height, age, sex\], based on Knudson 83 normative values).

The Change From Baseline in ALS Functional Rating Scale-Revised (ALSFRS-R) Total Score to the Average of Values Obtained at the End of Weeks 8 and 12 of Double-blind Treatment
Baseline, 8 weeks, 12 weeks

The ALSFRS-R is used to measure the progression and severity of disease; it consists of 12 questions, assessing a patient's capability and independence in functional activities relevant to ALS, categorized in 4 domains: gross motor tasks, fine motor tasks, bulbar functions, and respiratory function. Each question is scored from 0 (indicating incapable or dependent) to 4 (normal). The total score ranges from 0 to 48, with higher scores reflecting more normal function and lower scores reflecting more impaired function.

Number of Participants with Adverse Events as a Measure of Safety and Tolerability
21 days

Safety and tolerability of CK-2017357 after multiple oral doses to steady state in patients with ALS

Effect of single dose of CK-2017357 on number of contractions, time and work to onset of claudication during bilateral heel raises
1 day

Heel raises will be monitored by an electrogoniometer placed on the index leg and performed once every other second until onset of claudication pain or fatigue as determined by electrogoniometry

Effect of single dose of CK-2017357 on number of contractions, time and work to intolerable claudication pain or maximal calf muscle fatigue
1 day

Heel raises will be monitored by an electrogoniometer placed on the index leg and performed once every other second until limited by intolerable claudication pain or fatigue as determined by electrogoniometry

Effect of single dose of CK-2017357 on Six-Minute Walk Test
1 day

Patient's self-paced walking distance over 6 minutes

ALSFRS-R
2 days

An instrument for evaluating the functional status of patients with ALS. Minimum score is 0 and maximum score is 40. The higher the score the more function is retained.

Maximum grip strength
2 days

Measured using the DynEx Electronic Hand Dynamometer. Patients asked to squeeze the device with the maximum possible force to establish the maximum voluntary contraction.

Maximum grip strength fatigability
2 days

Handgrip fatigue is measured using the DynEx Electronic Hand Dynamometer. Patient is asked to squeeze the device until they can no longer stay above 60% of target or 120 seconds.

Shoulder extension fatigue
2 days

Patient is asked to hold one arm outstretched in front of them at a 90 degree angle. The time the arm falls below 90 degrees for \> 2 seconds will be recorded, up to a total evaluation time of 2 minutes. This is then repeated with the other arm.

Slow Vital Capacity (SVC)
2 days

SVC is measured using the Puritan Bennett Renaissance II Spirometry System and accessories.

Maximum Voluntary Ventilation (MVV)
2 days

MVV is the volume of air that can be exhaled during 12 seconds of rapid deep breathing. The actual volume is extrapolated to one minute. the Puritan Bennett Renaissance II Spirometry System and accessories is used for this measurement.

Sniff Inspiratory Pressure (SNIP)
2 days

SNIP is measured at Functional Residual Capacity, the bottom of the tidal breathing cycle, through one plugged nostril while the other remains open using the Micro Medical MicroRPM Respiratory Pressure Meter

Maximum Voluntary Muscle Contraction (MVC)
2 days

MVC is measured using the MicroFET 2 HHD.

Repeated Sub-Maximum Grip Strength Fatigability
2 days

Sub-Maximum Grip Strength Fatigability is measured using the DynEx Electronic Hand. Dynamometer

Secondary Endpoints

Change From CY 4031 Baseline in Percent Predicted Slow Vital Capacity to Week 24 in CY 4033
baseline and 24 weeks
Change From CY 4031 Baseline in Percent Predicted Slow Vital Capacity to Week 48 in CY 4033
baseline and 48 weeks
Change From CY 4031 Baseline in ALS Functional Rating Scale - Revised (ALSFRS-R) Total Score at Week 24
baseline and 24 weeks
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Delayed Start TreatmentEXPERIMENTALThe Delayed Start Treatment group consisted of patients who received placebo in CY 4031 and tirasemtiv in CY 4033.
Early Start TreatmentEXPERIMENTALThe Early Start Treatment group consisted of patients who received tirasemtiv in both CY 4031 and CY 4033.
Group 1 - PlaceboPLACEBO_COMPARATORDay 1 through Week 48: 2 placebo tablets twice daily
Group 2 - 250 mg tirasemtivEXPERIMENTALDay 1 through Week 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM
Group 3 - 375 mg tirasemtivEXPERIMENTALDay 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 through 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM
Group 4 - 500 mg tirasemtivEXPERIMENTALDay 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in PM; Weeks 3 and 4: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM; Weeks 5 through 48: 2 tablets of tirasemtiv (250 mg) in the AM and 2 tablets of tirasemtiv (250 mg) in the PM
CK-2017357EXPERIMENTAL125 mg tablets
PlaceboPLACEBO_COMPARATORPlacebo tablets
Dose Titration of CK-2017357 (Group 1)EXPERIMENTALDose titration of active drug as add-on therapy to riluzole
Matching Placebo (Group 2)PLACEBO_COMPARATORPlacebo as add-on therapy to riluzole
Matching PlaceboPLACEBO_COMPARATOR -
Active Drug Low Dose (CK-2017357 125 mg)EXPERIMENTAL -
Active Drug Mid Dose (CK-2017357 250 mg)EXPERIMENTAL -
Active Drug High Dose (CK-2017357 375 mg)EXPERIMENTAL -
Treatment Sequence 1EXPERIMENTALDosing Period 1 - Placebo; Dosing Period 2 - 375 mg CK-2017357; Dosing Period 3 - 500 mg CK-2017357
Treatment Sequence 2EXPERIMENTALDosing Period 1 - Placebo; Dosing Period 2 - 500 mg CK-2017357; Dosing Period 3 - 375 mg CK-2017357
Treatment Sequence 3EXPERIMENTALDosing Period 1 - 375 mg CK-2017357; Dosing Period 2 - Placebo; Dosing Period 3 - 500 mg CK-2017357
Treatment Sequence 4EXPERIMENTALDosing Period 1 - 375 mg CK-2017357; Dosing Period 2 - 500 mg CK-2017357; Dosing Period 3 - Placebo
Treatment Sequence 5EXPERIMENTALDosing Period 1 - 500 mg CK-2017357; Dosing Period 2 - Placebo; Dosing Period 3 - 375 mg CK-2017357
Treatment Sequence 6EXPERIMENTALDosing Period 1 - 500 mg CK-2017357; Dosing Period 2 - 375 mg CK-2017357; Dosing Period 3 - Placebo

Interventions

NameTypeDescription
tirasemtivDRUGOral
Placebo tabletsDRUG -
CK-2017357DRUGCK-2017357 125 mg tablets twice daily
RiluzoleDRUGTablets
PlaceboDRUGMatching placebo tablets BID for 21 days
Riluzole 50 MGDRUG -
Placebo (Part A)DRUGPlacebo tablets once daily for 14 days (Part A)
CK-2017357 (Part A)DRUGOne 125 mg CK-2017357 tablet once daily for 14 days (Part A)
Riluzole 50 MG (Part B)DRUGOne 50 mg tablet once daily for 14 days (Part B)
Placebo (Part B)DRUGPlacebo tablets once daily for 14 days (Part B)
CK-2017357 (Part B)DRUGOne 125 mg tablet once daily for 14 days (Part B)
375 mg CK-2017357DRUG375 mg CK-2017357 in capsules administered as a single oral dose.
500 mg CK-2017357DRUG500 mg CK-2017357 in capsules administered as a single oral dose.
250 mg CK-2017357DRUG250 mg CK-2017357 in capsules administered as a single oral dose.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites67

Inclusion Criteria: * Able to comprehend and willing to sign an Informed Consent Form (ICF). If verbal consent is given, a Legal Designee of the patient must sign the ICF form * Completed participation on study drug and the Follow-Up Visit in the CY 4031 study * Male patients, who have not had a va...

Countries:United StatesBelgiumCanadaFranceGermanyIrelandItalyNetherlandsPortugalSpainUnited Kingdom
Unlock Eligibility Criteria

Frequently asked questions about CK-2017357

What is CK-2017357 used for?

CK-2017357 was studied in Phase 2 clinical trials for amyotrophic lateral sclerosis (ALS) and for intermittent claudication in patients with peripheral artery disease. It is an investigational small molecule and has not been approved for any indication. All four of its clinical trials have been completed.

Who is developing CK-2017357?

CK-2017357 was developed by Cytokinetics, Incorporated, which trades on the Nasdaq under the ticker CYTK. The company sponsored the Phase 2 clinical program evaluating the drug in amyotrophic lateral sclerosis and in intermittent claudication associated with peripheral artery disease.

What phase is CK-2017357 in?

CK-2017357 is in Phase 2. Four Phase 2 trials have been completed, and none are currently active. The studies enrolled a total of 854 participants and included randomized, double-blind, placebo-controlled designs. The drug remains investigational and has not been approved by the FDA.

What clinical trials is CK-2017357 in?

CK-2017357 has been evaluated in four completed Phase 2 trials: NCT01709149, a 711-patient ALS study across the United States, Canada, and several European countries; NCT01486849 and NCT01378676, smaller ALS studies in the United States; and NCT01131013, a 61-patient study in intermittent claudication and peripheral artery disease.